Prostate Cancer Screening Has Changed: What Men Need to Know About the New 2026 Guidelines

The American Cancer Society now recommends regular PSA screening for most men between 50 and 69. Here’s why the advice has changed, who should start earlier, and how new testing strategies can reduce unnecessary procedures.
For years, the advice about prostate cancer screening was essentially: Talk to your doctor and decide whether testing is right for you.
That advice reflected a genuine medical debate. While the PSA blood test could detect prostate cancer early, doctors were concerned that screening could also identify slow-growing cancers that might never threaten a man’s life. Some men underwent unnecessary biopsies and treatments, sometimes experiencing complications such as urinary incontinence and erectile dysfunction.
Now, that conversation has taken an important turn.
In November 2026, the American Cancer Society (ACS) released its first major revision of its prostate cancer screening recommendations since 2010. The new guideline recommends regular PSA blood testing for most men between ages 50 and 69, with earlier and more frequent screening for men at higher risk.
The biggest change isn’t simply that more men are being encouraged to get screened. It’s that we now have better ways to investigate an abnormal result without automatically sending someone for a biopsy or treatment.
Let’s look at what changed and why it matters.
1. What exactly is new in the 2026 guidelines?
The recommendations now provide clearer screening schedules based on age and individual risk.
Who should be screened?
New ACS recommendation
Men at average risk- PSA blood test every 2 years, ages 50–69
Black men- Begin at 45; PSA every year through age 69
Men with a strong family history-Begin at 45; PSA every year through age 69
Men with one close relative diagnosed at 65 or older-Begin at 45; PSA every 2 years through age 69
Men ages 70–74-Individual decision with their doctor; every 2 years if continuing
Men 75 and older-Routine screening generally not recommended; exceptional decisions may be considered for very healthy men ages 75–79
Men with a life expectancy under 10 years-Screening not recommended.
A close family member generally means a father, brother, or son. A strong family history includes a close relative diagnosed before age 65 or multiple close relatives diagnosed with prostate cancer.
Men with known inherited cancer-risk mutations, such as BRCA2, may need a different and earlier screening strategy and should discuss this with their healthcare provider.
One important point: These are screening recommendations for men without symptoms. Someone experiencing urinary symptoms, blood in the urine, or other concerning symptoms needs an appropriate medical evaluation regardless of age or screening schedule.
2. What is a PSA test, and why is it important?
PSA stands for prostate-specific antigen. It is a protein produced by the prostate gland and measured through a simple blood test.
PSA levels can rise for several reasons, including:
Prostate cancer.
Benign enlargement of the prostate, which becomes increasingly common with age.
Prostate inflammation or infection.
Other temporary factors.
This is why an elevated PSA does not automatically mean cancer.
For many years, one of the biggest challenges with PSA screening was what happened after an abnormal result. Men could undergo biopsies and discover cancers that were so slow-growing they might never have caused a health problem.
The new recommendations address this concern by changing the approach to follow-up testing.
3. Why did the American Cancer Society change its recommendations?
There are three important reasons.
A. We now have stronger evidence that screening saves lives
Earlier studies of PSA screening produced conflicting results. One major European study showed that screening reduced deaths from prostate cancer, while a large US study did not demonstrate the same benefit.
Over time, however, longer follow-up of these studies has provided stronger evidence that PSA screening can reduce prostate cancer deaths and the likelihood of developing advanced disease.
The European screening trial, for example, has now demonstrated a sustained reduction in prostate cancer mortality over more than two decades of follow-up.
The important distinction is that screening is not necessarily beneficial simply because it finds more cancers. Its value is in identifying potentially dangerous cancers early enough to make a difference.
B. Fewer men were being screened, and advanced prostate cancer diagnoses increased
After the US Preventive Services Task Force recommended against routine PSA screening in 2012, PSA testing declined.
Over the following years, doctors began seeing an increase in advanced-stage prostate cancer diagnoses.
This raised concerns that some men were missing the opportunity to identify cancer at an earlier, more treatable stage.
The new ACS recommendations reflect a growing recognition that avoiding unnecessary screening also carries risks.
C. We have better tools to reduce the harms of screening
This may be the most important development.
An abnormal PSA used to lead more directly to a prostate biopsy. Today, there are additional steps that can help determine whether a biopsy is actually necessary.
The new guideline incorporates these approaches into the screening pathway.
4. An elevated PSA does NOT automatically mean a biopsy
This is an important message for men who may be hesitant about screening.
Under the new recommendations, the next steps are more deliberate.
Step 1: Repeat the PSA blood test.
For men ages 45–69, a PSA of 3.0 ng/mL or higher is considered elevated for the purposes of this guideline. For men ages 70–74, the threshold is 6.5 ng/mL or higher.
An elevated result should generally be repeated within 2 weeks to 3 months before proceeding with further investigations.
PSA levels can fluctuate, and a repeat test may show that the initial elevation was temporary.
Step 2: Consider an MRI or additional blood or urine testing.
If the PSA remains elevated, most men should be offered a prostate MRI and/or a validated biomarker test.
These tests can help estimate the likelihood of clinically significant cancer and determine whether a biopsy is appropriate.
Step 3: Decide whether a biopsy is necessary.
A prostate biopsy involves taking small tissue samples from the prostate to look for cancer cells.
MRI and biomarker testing can help doctors avoid unnecessary biopsies while identifying men who need further investigation.
A biopsy may still be necessary when the overall suspicion of cancer is high.
5. What happens if prostate cancer is found?
Finding prostate cancer does not always mean immediate surgery, radiation, or other treatment.
Some prostate cancers grow very slowly and may never become life-threatening.
For men diagnosed with low-risk prostate cancer, the ACS now recommends offering active surveillance as the initial management approach.
What does that mean?
Instead of immediately treating the cancer, doctors monitor it over time using:
Regular PSA blood tests.
Periodic prostate MRI.
Repeat biopsies when appropriate.
If there are signs that the cancer is becoming more aggressive, treatment can be considered.
This approach helps many men avoid or delay the potential side effects of treatment, including urinary incontinence and sexual dysfunction, without ignoring the cancer.
The goal is to treat the cancers that need treatment while avoiding unnecessary intervention for those that do not.
6. Why are Black men and men with a family history screened earlier?
Not all men have the same risk of developing prostate cancer.
Black men in the United States experience substantially higher rates of prostate cancer and are more likely to develop aggressive disease and die from it.
Similarly, having a father, brother, or son diagnosed with prostate cancer, particularly at a younger age, increases a man’s risk.
For these reasons, the ACS recommends starting PSA screening at age 45 for Black men and men with a strong family history.
These recommendations are an important step toward addressing disparities in prostate cancer diagnosis and outcomes.
7. Does every man need PSA screening indefinitely?
No.
Screening decisions become more complicated as men get older because the potential benefits take years to emerge, while the risks of unnecessary testing and treatment increase with age and other health conditions.
The ACS recommends individualized decision-making for men ages 70–74.
Routine screening is generally not recommended after age 75, and screening is discouraged after age 80. Men with a life expectancy under 10 years are also unlikely to benefit.
Overall health matters just as much as chronological age.
The PreventionOnly perspective: Better screening, smarter prevention
The new prostate cancer screening guidelines represent an important shift in preventive healthcare.
For years, the debate focused on whether screening did more good than harm. Today, stronger evidence supports screening, while advances in MRI, biomarker testing, and active surveillance provide better ways to minimize unnecessary procedures and treatment.
The message is not that every man needs more testing. It is that men should have the right testing at the right age, based on their individual risk, with a thoughtful plan for what happens next.
At PreventionOnly, we believe prevention is about more than ordering tests. It is about understanding individual risk, interpreting health information in context, and helping people make informed decisions before disease becomes more difficult to treat.
Early detection matters. But intelligent, personalized early detection matters even more.
This article is for educational purposes and does not replace individualized medical advice. Discuss your prostate cancer screening plan with your healthcare provider.
Reference: Hoffman RM, Wolf AMD, Etzioni R, et al. American Cancer Society Guideline for the Early Detection of Prostate Cancer, 2026. CA: A Cancer Journal for Clinicians. 2026. doi:10.3322/caac.70112.




Comments